| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.17 | 0.004 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.006 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.2 | 0.009 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.02 |